至今,GenScript的服务及产品已被Cell, Nature, Science, PNAS等1300多家生物医药类杂志引用近万次,处于行业领先水平。NIH、哈佛、耶鲁、斯坦福、普林斯顿、杜克大学等约400家全球著名机构使用GenScript的基因合成、多肽服务、抗体服务和蛋白服务等成功地发表科研成果,再次证明GenScript 有能力帮助业内科学家Make research easy.

Proteomics reveal cap-dependent translation inhibitors remodel the translation machinery and translatome

Cell Rep. 2021-10; 
J J David Ho, Tyler A Cunningham, Paola Manara, Caroline A Coughlin, Artavazd Arumov, Evan R Roberts, Ashanti Osteen, Preet Kumar, Daniel Bilbao, Jonathan R Krieger, Stephen Lee, Jonathan H Schatz
Products/Services Used Details Operation
Custom Vector Construction … ARHGEF2 ORF cDNA construct and empty vector GenScript Cat#OHu26696 … ARHGEF2/GEF-H1 ORF cDNA construct (OHu26696) and empty vector were purchased from GenScript, and transfected using Effectene (QIAGEN) following manufacturer protocols. … Get A Quote

摘要

Tactical disruption of protein synthesis is an attractive therapeutic strategy, with the first-in-class eIF4A-targeting compound zotatifin in clinical evaluation for cancer and COVID-19. The full cellular impact and mechanisms of these potent molecules are undefined at a proteomic level. Here, we report mass spectrometry analysis of translational reprogramming by rocaglates, cap-dependent initiation disruptors that include zotatifin. We find effects to be far more complex than simple "translational inhibition" as currently defined. Translatome analysis by TMT-pSILAC (tandem mass tag-pulse stable isotope labeling with amino acids in cell culture mass spectrometry) reveals myriad upregulated proteins that drive h... More

关键词

DDX17, GEF-H1, JNK, RHOA, eEF1ε1, eIF4A, rocaglate, silvestrol, translation, zotatifin